ThursdayApr 29, 2021 2:01 pm

BioMedNewsBreaks – Healthy Extracts Inc. (HYEX) Continues to Strengthen Position in Plant-Based Health Industry

Healthy Extracts (OTCQB: HYEX) is committed to growth and has aligned its operations to focus on the plant-based health industry. Reflecting this focus, HYEX changed its name from Grey Cloak Tech to align with the company’s objectives and a “Live Life Young Again” strategy. “The company is making remarkable strides to strengthen its market positions in the plant-based health industry through its two key subsidiaries, the science-based BergaMet North America and Ultimate Brain Nutrients (‘UBN’),” reads a recent article. The company also achieved significant accomplishments in 2020, including a 71% increase in recorded gross revenue, despite the COVID pandemic, as…

Continue Reading

ThursdayApr 29, 2021 1:45 pm

BioMedNewsBreaks – RYAH Group Inc. Featured in Bell2Bell Podcast

RYAH Group, engaged in the development and commercialization of various innovative technology solutions for the plant-based medical industry, was featured in The Bell2Bell Podcast, a part of InvestorBrandNetwork’s (“IBN”) sustained effort to provide specialized content distribution via widespread syndication channels. RYAH’s CEO Gregory Wagner joined the latest episode to discuss the company’s 2021 goals and milestones, as well as provide an overview of RYAH’s business model and product offerings. “I came to the company two years ago, and the reason why I came here from a different career was because I was completely floored by the amount of data this…

Continue Reading

WednesdayApr 28, 2021 10:11 am

BioMedNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Pursues Market Access in Israel for ‘Covid-ID Lab’

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) today announced that it has delivered 2,000 of its rapid 25-minute PCR tests ("Covid-ID Lab") to an established medical distributor in Israel for clinical evaluation of Covid-ID Lab for the purpose of commercial regulatory approval and potential product distribution. According to the update, the Israeli distributor markets and distributes a range of medical products and diagnostics in Israel and surrounding Middle Eastern countries. Its customers include government and private institutions such as hospitals, pharmacies and a broad range of health care providers. "We are excited by the opportunity to expand potential distribution…

Continue Reading

WednesdayApr 28, 2021 9:36 am

BioMedNewsBreaks – RYAH Group Inc. to Begin Trading on CSE under RYAH Ticker

RYAH Group (formerly known as Prime Blockchain Inc.) has announced that, beginning Tuesday, May 4, its common shares will begin trading on the Canadian Securities Exchange (“CSE”) under the ticker symbol RYAH. In accordance with CSE policies, the company has filed the required listing statement on SEDAR. RYAH just recently closed a reverse takeover transaction of Potbotics Inc., consisting of a triangular merger between the company (formerly Prime Blockchain, Inc.), Potbotics and a wholly owned Florida subsidiary of the company. “This is another major step in our journey in transforming patient care through our remote, connected devices and data analytics,…

Continue Reading

TuesdayApr 27, 2021 3:08 pm

BioMedNewsBreaks – Predictive Oncology Inc.’s (NASDAQ: POAI) Helomics Featured in DojoLIVE! Interview

Predictive Oncology’s (NASDAQ: POAI) subsidiary company, Helomics, was recently featured on DojoLIVE!, an engaging podcast and interview forum that brings together technology, business and thought leaders from a wide range of industries. The company’s Chief Technical Officer, Mark Collins, PhD, joined the interview to discuss what Helomics is bringing to the table in the field of cancer research in the podcast titled “Can We Cure Cancer with Artificial Intelligence?” “At Helomics, we have a nice convergence of data that we’ve gathered from testing live tumors, tumors outside the patient body, on drugs, standard of care drugs, normal drugs that you…

Continue Reading

TuesdayApr 27, 2021 1:58 pm

BioMedNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Board Appointment of Dr. Joanne Curley

VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, today announced the appointment of Joanne Curley, Ph.D. to its board of directors. VistaGen’s board will be comprised of seven directors following Dr. Curley’s appointment. “Joanne brings more than 25 years of pharmaceutical industry experience across numerous key operational and therapeutic areas,” said Shawn Singh, chief executive officer of VistaGen. “Her track record of propelling seven products from early development through regulatory approval is impressive and reflects her extensive…

Continue Reading

MondayApr 26, 2021 2:24 pm

BioMedNewsBreaks – InnerScope Hearing Technologies Inc. (INND) Announces LOI to Launch a Subscription-Based App

InnerScope Hearing Technologies (OTC: INND), an emerging and disruptive leader in the direct-to-consumer hearing device and hearing health technology space, has signed a letter of intent (“LOI”) with Audio Cardio Inc., dba AudioCardio(TM). The agreement provides InnerScope with a worldwide license, except for Japan, Korea and China, for full commercial rights to develop, market and sell an InnerScope-branded, subscription-based mobile app utilizing AudioCardio proprietary software. The software includes the  clinically proven Threshold Sound Conditioning technology. The proposed transaction outlined in the agreement provides for both InnerScope and AudioCardio to achieve greater market penetration by focusing on enhancing the visibility and awareness…

Continue Reading

MondayApr 26, 2021 12:49 pm

BioMedNewsBreaks – United Medical Equipment Business Solutions Network Inc. Offers Unique Mobile Solution

United Medical Equipment (“UME,” “UMEBSNI”) has committed to help speed economic recovery by supplying rapid COVID-19 test kits. In addition, the company has even gone a step further by offering “a unique mobile solution that involves on-call onsite COVID-19 Rapid Testing Mobile units,” reads a recent article. This offering is regarded as essential during the pandemic. “These units involve mobile testing specialists and experienced medical staff members who provide onsite COVID-19 rapid testing. Capable of nationwide deployment for extended periods, they are especially beneficial for securing employee safety.” To view the full article, visit https://ibn.fm/5n61f About United Medical Equipment Business…

Continue Reading

MondayApr 26, 2021 12:10 pm

BioMedNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Advancing i/Blue(TM) Imaging Solution

Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company, is advancing its proprietary and patented i/Blue(TM) Imaging System. Imagin’s goal is to reduce the cost of treatment for patients with bladder cancer while also improving their chances of survival. Its solution “advances the blue light procedure by allowing surgeons to see the bladder wall under both white and blue light simultaneously in side-by-side presentation, whereas existing systems require surgeons to toggle back and forth between white and blue during the course of the procedure.” According to an article detailing this matter, the existing systems have proven disadvantageous because they…

Continue Reading

ThursdayApr 22, 2021 2:54 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Set to Start Potentially Pivotal Berubicin Trial

CNS Pharmaceuticals (NASDAQ: CNSP) is working to determine the efficacy of its lead drug candidate, Berubicin, for the treatment of glioblastoma multiforme (“GBM”), an aggressive type of brain cancer for which there is currently no cure. Promising results were demonstrated when another company completed a small Phase 1 trial well over a decade ago in which 44% of patients saw their disease stabilize or improve. One Berubicin patient was living cancer-free as of the most recent medical assessment in November, nearly 15 years after the Phase 1 trial (https://ibn.fm/JnFSS). “CNS now hopes to advance Berubicin to commercial production, with the…

Continue Reading

Official NewsWire Relationships

BIO Informa DGE Dynamic Global Events DTC Healthcare Conference Kiasco Reasearch Nexus Conferences Octane

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050